4Palomaki A, Malminiemi K, Solakivi T, et al. Ubiquinone supplementation during lovastatin treatment :effect on LDL oxidation ex vivo. J Lipid Res ,1998 ,39 (7) :1430- 1437.
5Lankin VZ , Tikhaze AK, Kukharchuk VV, et al.Antioxidants decreases the intensification of low density lipoprotein in vivo peroxidation during therapy with statins. Mol Cell Biochem ,2003 ,249 (1-2) : 129-140.
6Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and preventio. circulation,2003 ,107(3) : 363-369.
2Jianhui Zhu, Quyyumi AA, Norman JE, et al, Effects of total pathogen burden on coronary artery disease risk and C - reactive protein levels[J] .Am J Cardiol,2000,85 : 140 - 146.
3Wolf MG,Zasmeta G, Homykewycz S, et al. Plasma levels of C - reactive prorein after coronary stent implantation[J] .Eur Heart J,2000,21:1152 - 1158.
4Lenine B, Kalman J, Mayer L, et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure[J]. N Eng J Med, 1990,323:236- 241.
5Gabay C, Kushner I. Actue - phase proteins and other systemic responses to inflammation[J]. N Eng Med, 1999,340:448 - 454.
6Tataru MC,Heinrich J,Junker R,et al.C - reactive protein and the severity of atherosclerosis in myocardial infarction patients with stable angina pectoris[J]. Eur Heart J,2000,21 : 1000.
7Albert MA, Staggers J, Chew P, et al. Investigators. The pravastatin inflammation CRP evaluation ( PRINCE ) : rationale and design [ J ]. Am Heart J,2001,141(6) :893 - 898.
8Ridker PM, Rifai N, Clearfield M, et ,ak. Measurement - C - reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events[ J], N Engl J Med, 2001,344(26) : 1959 - 1965.
9Bustos C, Hemandez- Presa MA, Ortego M, et al. HMG- COA reductase inhibition by atorvastatin reduces neointial inflammation in a rabbit model of atherosclerosis[J] .J AM Coll Cardiol, 1998,32(7) :2057 - 2064.
10Torre - Amione - G, Kapadis - S, Benedia - S, et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction :a report from the Study of Left Ventricular Dysfunction(SOLVD) J Am Coil Cardiol, 1996,27 (5): 1201.
5Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. ] Am Coil Cardiol, 2013, 62(16): e147-239.
6Callender T, Woodward M, Roth G, et al. Heart failure care in low- and middle-income countries: a systematic review and meta- analysis. PLoS Med, 2014, 11(8): e1001699.
7Roger VL, Weston SA, Redfield MM, et al. Trends in heart failure incidence and survival in a community-based population, lAMA, 2004, 292(3): 344-350.
8Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl ] Med, 2002, 347(18): 1397-1402.
9Folkers K, Vadhanavikit S, Mortensen SA, et al. Biochemical rationale and myocardial tissue data on the effective therapy of cardiomyopathy with coenzyme QlO. Proc Natl Acad Sci USA, 1985, 82(3): 901-904.
10Molyneux SL, Florkowski CM, George PM, et al. Coenzyme Q10: an independent predictor of mortality in chronic heart failure. ] Am Coll Cardiol, 2008, 52(18): 1435-1441.
